CAM
URGN icon

Cormorant Asset Management’s UroGen Pharma URGN Stock Holding History

Cormorant Asset Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-300,000
Closed -$3.19M – 48
2024
Q4 		$3.19M Sell
300,000
-1,250,000
-81% -$15M 0.18% 42
2024
Q3 		$19.7M Sell
1,550,000
-100,000
-6% -$1.48M 1.04% 30
2024
Q2 		$27.7M Buy
+1,650,000
New +$23.5M 1.6% 22

Other funds holding URGN

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Cormorant Asset Management's URGN Position: Q1 2025 in Review

Cormorant Asset Management sold out of UroGen Pharma (URGN) in Q1 2025, closing a stake of 300,000 shares — an estimated $3.19M sold.

Cormorant Asset Management first reported a position in URGN in Q2 2024 and held it in 3 quarters. The position peaked at $27.7M in Q2 2024. 139 funds tracked by Wall St. Rank hold URGN as of Q1 2025.

  • Cormorant Asset Management reported no remaining UroGen Pharma position as of Q1 2025 after selling out during the quarter.
  • Cormorant Asset Management sold 300,000 UroGen Pharma shares in Q1 2025, an estimated $3.19M.
  • Cormorant Asset Management first reported a position in UroGen Pharma in Q2 2024 and held it in 3 quarters.
  • Cormorant Asset Management's UroGen Pharma position peaked at $27.7M in Q2 2024.
  • 139 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2025.

Based on Cormorant Asset Management's 13F filing for Q1 2025, filed 15 May 2025.